FNY Managed Accounts’s Gyre Therapeutics GYRE Stock Holding History

FNY Managed Accounts’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-53	Closed	-$2K	–	719
2017 Q3	$2K	Buy	+53	New	+$1.59K	﹤0.01%	578

Other funds holding GYRE

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FNY Managed Accounts's GYRE Position: Q4 2017 in Review

FNY Managed Accounts sold out of Gyre Therapeutics (GYRE) in Q4 2017, closing a stake of 53 shares — an estimated $2K sold.

FNY Managed Accounts first reported a position in GYRE in Q3 2017 and held it in 1 quarter. The position peaked at $2K in Q3 2017. 35 funds tracked by Wall St. Rank hold GYRE as of Q4 2017.

FNY Managed Accounts reported no remaining Gyre Therapeutics position as of Q4 2017 after selling out during the quarter.
FNY Managed Accounts sold 53 Gyre Therapeutics shares in Q4 2017, an estimated $2K.
FNY Managed Accounts first reported a position in Gyre Therapeutics in Q3 2017 and held it in 1 quarter.
FNY Managed Accounts's Gyre Therapeutics position peaked at $2K in Q3 2017.
35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2017.

Based on FNY Managed Accounts's 13F filing for Q4 2017, filed 23 Jan 2018.